<DOC>
<DOCNO>EP-0618223</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31415	A61K31415	A61K3800	A61K3800	C07C23500	C07C23534	C07C23700	C07C23722	C07C23742	C07C27100	C07C27122	C07C27124	C07C27128	C07C27130	C07C31100	C07C31138	C07C31147	C07C32700	C07C32720	C07C33300	C07C33318	C07D20700	C07D20710	C07D20900	C07D20942	C07D23300	C07D23364	C07D27700	C07D27756	C07K100	C07K1113	C07K500	C07K502	C07K506	C07K508	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07K	C07K	C07K	C07K	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K38	A61K38	C07C235	C07C235	C07C237	C07C237	C07C237	C07C271	C07C271	C07C271	C07C271	C07C271	C07C311	C07C311	C07C311	C07C327	C07C327	C07C333	C07C333	C07D207	C07D207	C07D209	C07D209	C07D233	C07D233	C07D277	C07D277	C07K1	C07K1	C07K5	C07K5	C07K5	C07K5	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula R-A
1
-A
2
-X-A
3
 wherein R i H, a protecting group 
or optionally substituted benzyloxy, A
1
 is an α-hdroxy or α-amino 
acid residue or a radical (α) as defined hereinafter, A
2
 is an 
α-hydroxy or α-amino acid residue or A
1
 and A
2
 form together a 
pseudo-dipeptide or a dipeptide mimetics residue or a radical (aa), 

(bb) or (cc) as defined hereinafter, X is a residue derived from Asp 
wherein A
3
 is -CH
2
 -X
1
-C0-Y
1
, -CH
2
-0-Y
2
, -CH
2
-S-Y
3
 or -CH
2
-(C0)
m
-Y
6
 
wherein X
1
 is 0 or S, m is 0 or 1 and Y
1
, Y
2
, Y
3
 and Y
6
 are as 
defined herein after, have pharmacological activity, e.g. IL-1β 

release inhibiting properties. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SANDOZ AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ LTD
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ LTD.
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.
</APPLICANT-NAME>
<APPLICANT-NAME>
SANDOZ-PATENT-GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HENG RICHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
LEUTWILER ALBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
REVESZ LASZLO
</INVENTOR-NAME>
<INVENTOR-NAME>
WUETHRICH HANS-JUERG
</INVENTOR-NAME>
<INVENTOR-NAME>
HENG, RICHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
LEUTWILER, ALBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
REVESZ, LASZLO
</INVENTOR-NAME>
<INVENTOR-NAME>
WUETHRICH, HANS-JUERG
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention relates to peptides having pharmaceutical. 
utility, processes for their production, pharmaceutical compositions 
comprising them and their use as pharmaceuticals. More particularly the present invention provides a compound of 
formula I 
R-A₁-A₂-X-A₃   (I)wherein 
Ris hydrogen, an amino or hydroxy protecting group or 
optionally ring substituted benzyloxy, A₁is an α-hydroxy acid residue; an amino acid residue or a 
thiocarbonyl analogue thereof having each an optionally 
protected side chain; or a radical of formula (α) 
 
wherein ring A is optionally substituted by hydroxy or 
C₁₋₄alkoxy and Ra is CO or CS and either
 
 
i) A₂ is an α-hydroxy acid residue, -NH-CHR₃-CO- 
wherein 
R₁is C₁₋₄alkyl R₂is H, halogen, C₁₋₄alkyl, CF₃ or trityl, R₃is an optionally protected side chain residue of an 
α-amino acid, and Yis C₂₋₅alkylene optionally substituted by OH, CH₃, C₂H₅, 
oxo, ketal or halogen, Xis a radical of formula (a) or (b) 
 
wherein R₇ is -CO₂H, -CONHOH or a bioisosteric group, A₃is -CH₂-X₁-CO-Y₁; -CH₂-O-Y₂; or -CH₂-S-Y₃; wherein X₁ is 0 or 
S, Y₁ is a cycloaliphatic residue; optionally substituted 
aryl; optionally ring substituted diphenylmethyl; piperidino; 
or optionally substituted mono-, bi- or tricyclic heteroaryl; 
Y₂ is a cycloaliphatic residue; optionally ring substituted 
diphenylmethyl; or optionally substituted bi- or tricyclic 
heteroaryl; Y₂ being also optionally substituted pyridyl or 
aryl when A₁ is other than an α-hydroxy acid residue and A₂  
 
is other than -NH-CHR₃-CO-; and Y₃ is a cycloaliphatic 
residue; tri-(C₁₋₄alkyl)methylcarbonyl, di-(C₁₋₄alkyl)aminothiocarbonyl, 
4-nitro-phenyl, 2,6-dichloro-benzoyl; 
2,3,6-trichloro-4-pyridyl, a 5-membered nitrogen-containing 
heterocyclic radical or optionally substituted bi- or 
tricyclic heteroaryl; Y₃ being also optionally substituted 
pyridyl or aryl when A₁ is other than an α-hydroxy acid 
residue and A₂ is other than -NH-CHR₃-CO-; or
 
ii) A₂ is a radical of formula (c) 
   wherein 
R₄is H or C₁₋₄alkyl R₆is CO or CS Y₄is -(CH₂)s- N(C₁₋₄alkyl)₂ or optionally 
protected -(CH₂)s―NH-cyclohexyl wherein s is 
1, 2, 3 or 4; or A₁ and A₂ form together a radical of formula (aa), (bb) or 
(cc) 
   wherein R1a and R₅ form together C₂₋₅alkylene or 
C₂₋₅alkenylene and Y₅ is an optionally protected side  
 
chain residue of an α-amino acid; or Y₅ has one of the 
significances given above for Y₄,
 
or R₅ and Y₅ form together 
or R₅ is 2,3-dihydro-2-indanyl, 
Y₅ is H and R1a has independently one of 
the significance given
</DESCRIPTION>
<CLAIMS>
A compound of formula I 
R-A₁-A₂-X-A₃   (I) 

wherein 
R is hydrogen, an amino or hydroxy protecting group or optionally 

ring substituted benzyloxy, 
A₁ is an α-hydroxy acid residue; an amino acid residue or a 

thiocarbonyl analogue thereof having each an optionally protected 
side chain; or a radical of formula (α) 

 
wherein ring A is optionally substituted by hydroxy or 

C₁₋₄alkoxy and Ra is CO or CS 
and either 

i) A₂ is an α-hydroxy acid residue, -NH-CHR₃-CO- 
 

wherein 
R₁is C₁₋₄alkyl R₂is H, halogen, C₁₋₄alkyl, CF₃ or trityl, R₃is an optionally protected side chain residue of an 

α-amino acid, and Yis C₂₋₅alkylene optionally substituted by OH, CH₃, C₂H₅, 
oxo, ketal or halogen, Xis a radical of formula (a) or (b) 

 
wherein R₇ is -CO₂H, -CONHOH or a bioisosteric group, A₃is -CH₂-X₁-CO-Y₁; -CH₂-O-Y₂; or -CH₂-S-Y₃; wherein X₁ is O or 

S, Y₁ is a cycloaliphatic residue; optionally substituted 
aryl; optionally ring substituted diphenylmethyl; piperidino; 

or optionally substituted mono-, bi- or tricyclic heteroaryl; 
Y₂ is a cycloaliphatic residue; optionally ring substituted 

diphenylmethyl; or optionally substituted bi- or tricyclic 
heteroaryl; Y₂ being also optionally substituted pyridyl or 

aryl when A₁ is other than an α-hydroxy acid residue and A₂ 
is other than -NH-CHR₃-CO-; and Y₃ is a cycloaliphatic 

residue; tri-(C₁₋₄alkyl)methylcarbonyl, di-(C₁₋₄alkyl)aminothiocarbonyl, 
4-nitro-phenyl, 2,6-dichloro-benzoyl; 

2,3,6-trichloro-4-pyridyl, a 5-membered nitrogen-containing 
heterocyclic radical or optionally substituted bi- or 

tricyclic heteroaryl; Y₃ being also optionally substituted 
pyridyl or aryl when A₁ is other than an α-hydroxy acid 

residue and A₂ is other than -NH-CHR₃-CO-;  
   or 

ii) A₂ is a radical of formula (c)  
wherein 

R₄is H or C₁₋₄alkyl R₆is CO or CS Y₄is -(CH₂)s- N(C₁₋₄alkyl)₂ or optionally 
protected -(CH₂)s―NH-cyclohexyl wherein s is 

1, 2, 3 or 4;  
or A₁ and A₂ form together a radical of formula (aa), (bb) or 

(cc) 
 

wherein R1a and R₅ form together C₂₋₅alkylene or 
C₂₋₅alkenylene and Y₅ is an optionally protected side chain 

residue of an α-amino acid; or Y₅ has one of the significances 
given above for Y₄, 

or R₅ and Y₅ form together 
 

or R₅ is 2,3-dihydro-2-indanyl, 
Y₅ is H and R1a has independently one of 

the significance given for R1b, and 
R1bis an optionally protected side chain of the amino acid 

residue or thiocarbonyl analogue A₁ indicated above, 
 

or A₁ and A₂ form together a pseudo-dipeptide or a dipeptide 
mimetics residue, 

X is a radical of formula (a) or (b) as defined above, and 
A₃ is -CH₂-X₁-(CO)m-Y₆ wherein X₁ is as defined above, m is 0 or 

1 and Y₆ is a cycloaliphatic residue; tri-(C₁₋₄alkyl)methyl; 
optionally ring substituted diphenylmethyl; optionally 

substituted aryl; or an optionally substituted mono-, di- or 
tricyclic heteroaryl residue 

with the provisos that 

i)Y₁ in A₃ is other than optionally substituted aryl or pyridyl 
when A₁ is other than an α-hydroxy acid residue, A₂ is 

-NH-CHR₃-CO- and R₇ in (a) or (b) is optionally esterified 
COOH, 
ii)Y₅ in (aa) is in R configuration when it is the residue of an 
optionally protected side chain residue of an α-amino acid, Y₆ 

is optionally substituted aryl and R₇ is optionally esterified 
COOH, 
 
and the physiologically-hydrolysable and -acceptable esters or 

amides thereof when R₇ is -CO₂H, 
in free form, in salt form or in the form of complexes. 
A compound according to Claim 1 wherein A₂ is 
 

X is a radical of formula (a) as defined in Claim 1 and A₃ is 
-CH₂-X₁-CO-Y₁, -CH₂-O-Y₂ or -CH₂-S-Y₃ wherein Y, Y₁, Y₂, Y₃ and 

X₁ are as defined in Claim 1. 
A compound according to Claim 1 wherein A₁ is an α-hydroxy acid 
residue, X is a radical of formula (a) as defined in Claim 1, A₂ 

is -NH-CHR₃-CO- and A₃ is -CH₂-X₁-CO-Y₁, -CH₂-O-Y₂ or -CH₂-S-Y₃ 
wherein R₃, X₁, Y₁ and Y₂ are as defined in Claim 1 and Y₃ is a 

 
cycloaliphati
c residue or a 5-membered nitrogen-containing 
heterocyclic radical. 
A compound according to Claim 1 wherein A₁ is other than an 
α-hydroxy acid residue, A₂ is an α-hydroxy acid residue, X is a 

radical of formula (a) as defined in Claim 1 and A₃ is 
-CH₂-X₁-CO-Y₁, -CH₂-O-Y₂ or -CH₂-S-Y₃ wherein X₁, Y₁, Y₂ and Y₃ 

are as defined in Claim 1. 
A compound according to Claim 1 wherein A₁ and A₂ form together a 
radical of formula (aa) wherein R1a and R₅ form together 

C₂₋₅alkylene, -CHY₅-CO- has the D configuration, X is a radical 
of formula (a) as defined in Claim 1 and A₃ is -CH₂-X₁-(CO)m-Y₆ 

wherein Y₆ is optionally substituted aryl or pyridyl. 
A compound according to Claim 1 wherein A₁ and A₂ form together a 
dipeptide mimetics residue. 
A compound according to Claim 1 wherein A₁ and A₂ form together a 
dipeptide mimetics residue of formula -NH-CHR1b-W₁- wherein R1b 

is as defined in Claim 1 and W₁ is 
 

a residue of formula -NH-W₂- wherein W₂ is 
 

or a residue of formula -O-W₃- as defined in Claim 1. 
A process for the preparation of a compound of formula I as 
defined in Claim 1, which process comprises: 
a) removing at least one protecting group from a compound of 
formula I in protected form or adding a protecting group R at the 

terminal group of a compound of formula I; or 
b) converting one compound of formula I into another compound of 
formula I; or 
c) coupling together by an amide bond two peptide fragments, each of 
which contains at least one amino acid in protected or 

unprotected form and one peptide fragment containing a radical of 
formula (a) or (b) as defined in Claim 1, the peptide fragments 

being such that a protected or unprotected peptide having the 
sequence according to formula I above is obtained and, if 

necessary, removing the protecting group or groups from a 
compound of formula I in protected form; or 
d) reacting a compound of formula II 
R-A₁-A₂-X-CH₂-Za   (II) 

wherein R, A₁, A₂ and X are as defined in Claim 1, and Za is a 
leaving group, with a compound of formula HX₁-(CO)m-Y₇ wherein X₁ 

and m are as defined in Claim 1 and Y₇ is Y₁, Y₂, Y₃ or Y₆ or a 
functional derivative thereof when m is 1; 
e) for the production of a compound of formula I wherein X is a 
radical of formula (a) or (b) monoalkylating or monoacylating a 

compound of formula III 

 

wherein R, A₁ and A₂ are as defined in Claim 1 and R₁₈ is an 
ester group, with a compound HX₁-(CO)m-Y₇ wherein m, X₁ and Y₇ 

are as defined above, or a functional derivative thereof when m 
is 1; 
 
and recovering a compound of formula I thus obtained in free or salt 

form or in the form of a complex. 
A compound of formula I according to any one of Claims 1 to 7, a 
physiologically-hydrolysable and -acceptable ester or amide 

thereof or a pharmaceutically acceptable salt thereof for use as 
a pharmaceutical. 
A pharmaceutical composition comprising a compound of formula I 
according to any one of Claims 1 to 7, a physiologically-hydrolysable 

and -acceptable ester or amide thereof or a 
pharmaceutically acceptable salt thereof together with a 

pharmaceutically acceptable diluent or carrier therefor. 
</CLAIMS>
</TEXT>
</DOC>
